(Total Views: 365)
Posted On: 11/19/2020 2:11:23 PM
Post# of 36566
buildit, this was just weird wording to me...
I mean, it has nothing to do with BK in Malaysia, so why would it bode well for them. BK will run their own trials and get approvals in Malaysia based on those, so nothing to do with China trials.
Quote:
Generex had on Nov 5, signed a framework agreement with the China CDC, Beijing Guoxin Haixiang Equity Investment Partnership and Beijing Youfeng International Consulting Co., Ltd to develop and commercialise the Covid-19 vaccine in China.
Bintai Kinden managing director Ong Choon Lui expects the collaboration between Generex and its China partners to advance the li-Key vaccine development platform.
He said the vaccine is the first product under this li-Key platform licence. This bode well for Bintai Kinden as it has the exclusive rights to distribute, sell and commercialise the vaccine in Malaysia, Brunei, Myanmar, Cambodia, Timor-Leste, Indonesia, Laos, the Philippines, Singapore, Thailand and Vietnam.
Bintai Kinden has also been given the first right of refusal to distribute and market the vaccine within Australia, New Zealand and the global halal market.
I mean, it has nothing to do with BK in Malaysia, so why would it bode well for them. BK will run their own trials and get approvals in Malaysia based on those, so nothing to do with China trials.
(0)
(0)
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.
